logo
Rohingya refugees in Bangladesh fear aid cuts will deepen crisis

Rohingya refugees in Bangladesh fear aid cuts will deepen crisis

Yahoo27-03-2025

By Ruma Paul
KUTUPALONG REFUGEE CAMP, Bangladesh (Reuters) - Majuna Khatun sat cradling her six-month-old baby at a rehabilitation centre for Rohingya refugees in Bangladesh, worried her child would be without critical healthcare due to funding cuts from the United States and some European countries.
"Where will I go if this facility closes?" 30-year-old Khatun said at the centre, where her child, whose tiny feet were strapped into orthopaedic braces, receives physiotherapy for clubfoot.
Bangladesh is sheltering more than 1 million Rohingya - members of the world's largest stateless population who fled violent purges in neighbouring Myanmar - in camps in the Cox's Bazar district, where they have limited access to jobs or education.
The decision by the administration of President Donald Trump to halt most foreign aid and dismantle the U.S. Agency for International Development (USAID) has caused turmoil in the humanitarian sector globally and the U.N. has warned that it will create dire conditions for refugees.
At the Bangladesh camps, Rohingya refugees fear the cuts will compound food and health issues and lead to a surge in crime.
"There are fewer doctors now. Rohingya volunteers who supported us have been dismissed. People are suffering because they can't get the treatment they need," said Mohammad Sadek, a 24-year-old Rohingya.
The U.S. has been the largest provider of aid to the Rohingya refugees, contributing nearly $2.4 billion since 2017, according to a State Department website.
The freeze on funds has forced five U.S.-funded hospitals to reduce services, Mohammed Mizanur Rahman, Bangladesh's top official overseeing the refugee camps, said last month.
About 48 health facilities, including 11 primary care centres, have also been affected, leaving many refugees without access to essential care, said Hasina Rahman, Bangladesh country director for the International Rescue Committee.
"Our priority (now) is to protect the most vulnerable, especially women, girls, and children," she said.
David Bugden, principal coordinator of the Inter-Sector Coordination Group, which oversees NGO efforts at Cox's Bazar, said around 300,000 refugees have been impacted by disruptions in healthcare services.
Bangladesh's foreign ministry and the U.S. embassy did not respond to requests for comment.
Gul Bahar's four-year-old daughter Mukarrama, suffers from cerebral palsy. She has been undergoing therapy for the past three years which has helped improve her condition.
"If this centre shuts down, we'll lose everything she's gained. I'll be back to square one," said Bahar, 32, her voice trembling.
HUNGER AND CRIME
The U.S. cuts and those by some European countries would worsen already dire conditions for the refugees, U.N. Secretary-General Antonio Guterres warned.
The U.N. World Food Programme (WFP) said it may be forced to halve the amount of food rations to $6 from April due to a funding shortfall, which would amount to 20 cents a day.
A previous round of ration cuts in 2023 that reduced the amount to $8 monthly led to a sharp increase in hunger and malnutrition, the U.N. has said. The cut was later reversed.
"We can't work outside the camp, and the rations we get are barely enough. If they reduce it further, crime will increase, people will do anything to survive," said Nojir Ahmad, a father of five, who fled to Bangladesh from Myanmar in 2017.
Rohingya camps have seen an upswing in crimes in recent years, according to police data.
About 70,000 Rohingya from Myanmar fled to Bangladesh last year, driven in part by growing hunger in their home state of Rakhine.
Aid cuts could make refugees more vulnerable to trafficking, radicalisation and exploitation, said a Bangladesh official, who did not want to be named as he was not authorised to speak to the media.
"Our food, healthcare, and education systems are collapsing," said Mohammad Jubair, a prominent Rohingya community leader. "If this gets out of hand, it won't just be a problem for Bangladesh - it will become a global issue."
Shofiul Islam was bedridden after falling from a tree five years ago. The 35-year-old said his world shrunk to the four walls of his shanty until the rehabilitation centre began treating him.
"I couldn't stand up or even turn in bed... because of them, I can move again," he said, using a forearm crutch to support himself.
"If it closes, all dreams will be shattered. People like me will have nowhere to turn."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit
RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Yahoo

time38 minutes ago

  • Yahoo

RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit

Health Secretary Robert F. Kennedy Jr. named eight new members to the CDC's Advisory Committee on Immunization Practices on Wednesday, including several anti-vaccine proponents, after dismissing all 17 existing advisers. Kennedy justified the overhaul to 're-establish public confidence in vaccine science,' claiming, without providing specific evidence, that prior Biden-appointed members had conflicts of interest. The new eight-member committee represents the minimum allowed under ACIP's founding charter. Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — Martin Kulldorff, a biostatistician and epidemiologist, was among eight individuals selected by Kennedy to join the Advisory Committee on Immunization Practices (ACIP). Kulldorff has been an outspoken critic of COVID-19 lockdowns and vaccine mandates. His appointment has also raised questions due to his paid involvement in litigation against a major vaccine manufacturer, according to Reuters. Citing court records, Reuters notes that Kulldorff served as an expert witness in lawsuits against Merck & Co Inc (NYSE:MRK) over its Gardasil vaccine, which is used to prevent cancers caused by the human papillomavirus (HPV). The plaintiff accused the pharmaceutical company of not properly disclosing the vaccine's risks. Gardasil was approved in the U.S. in 2006 after going through clinical trials to prove its safety and a deposition in October, Kulldorff acknowledged that he had been paid $400 an hour for his work on the case and had billed approximately $33,000 through September. He also received a $4,000 retainer in connection with the North Carolina lawsuit, which was part of a broader legal effort encompassing about 200 related cases. In March, a federal judge ruled in favor of Merck in that particular case. Kulldorff's paid role as a litigation consultant could conflict with ACIP's established rules. According to the committee's guidelines, members are prohibited from serving as paid expert witnesses or litigation consultants in cases involving vaccine manufacturers while actively serving on the panel. Gardasil/Gardasil 9 sales declined 41% to $1.33 billion in the first quarter of 2025, primarily due to lower demand in China, partially offset by higher demand in most international regions, particularly in Japan, and higher pricing and demand in the U.S. Excluding China, sales grew 14%, or 16%, excluding the impact of foreign exchange. Read Next: Are you rich? Here's what Americans think you need to be considered wealthy. Bezos' Favorite Real Estate Platform Launches A Way To Ride The Ongoing Private Credit Boom Photo: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article RFK Jr. Appointee To CDC Advisory Committee Was A Paid Expert In Merck's Gardasil Lawsuit originally appeared on Sign in to access your portfolio

Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland
Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland

Yahoo

time6 hours ago

  • Yahoo

Analysis of the European Hospitals Market 2025-2030: Investment Opportunities for Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Sweden, Belgium, and Ireland

The market is poised for growth, driven by aging demographics, technological advances, and a shift to value-based care. Key opportunities lie in digital health, infrastructure upgrades, and workforce development. Addressing workforce shortages and integrating value-based models will be crucial for sustainability. European Hospital Market Dublin, June 13, 2025 (GLOBE NEWSWIRE) -- The "Europe Hospital Market, By Country, Competition, Forecast and Opportunities, 2020-2030F" has been added to offering. The Europe Hospital Market was valued at USD 0.85 Trillion in 2024, and is expected to reach USD 1.09 Trillion by 2030, rising at a CAGR of 4.35%. This mature and advanced market is anchored by strong public healthcare systems, cutting-edge infrastructure, and a widespread commitment to universal care access. The sector's growth is being fueled by shifting demographics, especially aging populations, along with rapid technological progress and evolving patient expectations. To maintain performance and meet rising demand, hospitals are undergoing digital transformation, expanding service capacity, and focusing on operational modernization. Investments in digital health, workforce development, and facility upgrades are becoming critical. Meanwhile, the shift toward integrated, value-based care models is redefining hospital operations and emphasizing efficiency, outcome measurement, and long-term sustainability, ensuring hospitals remain central to Europe's healthcare landscape. Key Market Driver Aging Population and Chronic Disease Burden Europe's aging population and the resulting increase in chronic diseases are major factors propelling the hospital market. By 2030, the number of Europeans living with Alzheimer's and related dementias is expected to rise to 14 million, escalating the healthcare system's financial and operational demands. The projected economic impact of Alzheimer's care is set to exceed USD 721.37 billion by 2050. As per Eurostat, individuals aged 65 and older made up 21.1% of the EU's population in 2022, and this is forecasted to rise to 32.5% by 2100. Older populations are more prone to conditions such as cardiovascular disease, diabetes, osteoporosis, neurodegenerative disorders, and cancer, all of which increase hospital care needs. Consequently, hospitals are expanding geriatric and chronic care services, modernizing infrastructure, and adapting clinical operations to manage growing patient loads. Key Market Challenge Workforce Shortages and Talent Retention The shortage of skilled medical professionals - including nurses, general practitioners, and specialists - poses a significant challenge for hospitals across Europe. Contributing factors include an aging healthcare workforce, burnout, and early retirements, particularly in under-resourced public systems. Staffing shortages reduce care quality, extend wait times, and hinder hospitals' ability to scale operations or adopt innovative models. The increased use of temporary staffing and overtime also inflates labor costs. Addressing this challenge requires strategic investment in training programs, international recruitment, and adoption of automation technologies such as AI-driven diagnostics and robotic procedures to ease clinical burdens and improve workforce efficiency. Key Market Trend Integration of Value-Based Healthcare Models European hospitals are transitioning from fee-for-service to value-based healthcare (VBHC) models, which emphasize care quality, patient outcomes, and cost-effectiveness. Government mandates and payer incentives are accelerating this shift to improve healthcare delivery and financial sustainability. Hospitals are redesigning care pathways around bundled, patient-centered services with a focus on chronic disease management, preventative care, and post-discharge support. The implementation of performance-based KPIs is reshaping reimbursement models, promoting efficiency, and reducing readmissions. Advanced analytics and predictive tools are increasingly used to track outcomes, manage resources, and demonstrate value - ultimately strengthening hospitals' competitiveness and long-term viability in the evolving European health ecosystem. Key Market Players Profiled: HCA Healthcare UK Fresenius SE & Co. KGaA Spire Healthcare Group plc Orpea Group Asklepios Klinik Barmbek Sana Kliniken AG San Donato Group (Gruppo San Donato) Report Scope In this report, the Europe Hospital Market has been segmented into the following categories: Europe Hospital Market, By Product: Public Private Europe Hospital Market, By Type: General Specialty Multi-Speciality Europe Hospital Market, By Type of Services: In-Patient Services Out-Patient Services Europe Hospital Market, By Bed Capacity: Up to 100 beds 100-500 beds Above 500 beds Europe Hospital Market, By Country: Germany France United Kingdom Italy Spain Netherlands Switzerland Sweden Belgium Ireland Key Attributes Report Attribute Details No. of Pages 125 Forecast Period 2024-2030 Estimated Market Value (USD) in 2024 $0.85 Trillion Forecasted Market Value (USD) by 2030 $1.09 Trillion Compound Annual Growth Rate 4.3% Regions Covered Europe For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Hospital Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module
FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module

Yahoo

time8 hours ago

  • Yahoo

FDA grants 510(k) clearance to Viz.ai's Viz Subdural Plus module

The US Food and Drug Administration (FDA) has granted 510(k) clearance to for its Viz Subdural Plus module, designed for enhancing clinical decision-making. It is claimed to be the first solution to quantify the size of collections such as subdural haemorrhages (SDH) in the subdural space on non-contrast computed tomography images. This solution automatically labels subdural collections and reports measurements such as thickness, midline shift, and volume. According to the company, chronic subdural haematoma is anticipated to become the most prevalent cranial neurosurgical condition in the adult population by 2030 in the US, with an estimated 60,000 new cases each year. The precise assessment of subdural collections is crucial for assessing severity, tracking progression, and guiding timely interventions, particularly for those under consideration for MMA [middle meningeal artery] embolisation. The software solution is designed to streamline the analysis of subdural collections by automating a process that has traditionally been manual and laborious. Integrated into the One platform, the software is currently in use in 1,800 health systems and hospitals. The platform enhances disease detection, supports critical care decisions, and optimises care pathways to improve patient outcomes. product management senior director Justin Ryea said: 'With an ageing population, the incidence of chronic subdural hematomas is rising, and so is the need for intelligent, automated tools to assess volume when deciding on the appropriate intervention such as MMA embolisation. 'Viz Subdural Plus, along with intracerebral haemorrhage measurements, exemplify how we're expanding our capabilities in our market-leading Viz Neuro Suite to address high-impact conditions, reduce variability in care, and drive better outcomes at scale.' The company leverages AI algorithms and machine learning to expedite diagnosis and care in the US and European healthcare systems. Last year, disclosed new trial data evaluating its AI-powered neurovascular technology that can detect and diagnose various neurological pathologies, including acute ischemic stroke, cryptogenic stroke, unruptured incidental aneurysm (UIA), and brain haemorrhage. "FDA grants 510(k) clearance to Viz Subdural Plus module" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store